Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 201–300 of 1,003
Talley, N. J., Quan, C., Jones, M. P., & Horowitz, M. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00530.x · Cited by 133
Changes in neurohormonal gut peptides following bariatric surgery
Ochner, C. N., Gibson, C., Shanik, M., Goel, V, & Geliebter, A. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.132 · Cited by 134
Ratliff, J. C., Leite, J. O. M., de Ogburn, R., Puglisi, M. J., VanHeest, J. L., & Fernández, M. L. (2010) · Nutrition Research · doi:10.1016/j.nutres.2010.01.002 · Cited by 150
“Peptide YY is released in proportion to the amount of kilocalories ingested [41], so the energy intake at breakfast may have resulted in unexpected PYY levels despite the difference in macronutrient content.”
BackgroundTaste perception, associated hormonal modulation, and nutrient intake
Loper, H., Sala, M. L., Dotson, C. D., & Steinle, N. (2015) · Nutrition Reviews · doi:10.1093/nutrit/nuu009 · Cited by 140
Stanley, S., Wynne, K., & Bloom, S. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00536.2003 · Cited by 132
Self-citationHealth benefits of cereal fibre: a review of clinical trials
Smith, C. E., & Tucker, K. L. (2011) · Nutrition Research Reviews · doi:10.1017/s0954422411000023 · Cited by 129
“Peptide YY (PYY) and ghrelin have been shown to modulate food intake((28,29)).”
BackgroundBose, M., Oliván, B., Teixeira, J., Pi-Sunyer, F. X., & Laferrère, B. (2009) · Obesity Surgery · doi:10.1007/s11695-008-9696-3 · Cited by 128
“PYY3-36 has been shown to decrease food intake in humans [126] and regulates body weight in rodents [127].”
BackgroundThe Gut and Regulation of Body Weight
Wynne, K., Stanley, S., & Bloom, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0189 · Cited by 130
Self-citationBariatric surgery, bone loss, obesity and possible mechanisms
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., Baldock, P. A., & Center, J. R. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01050.x · Cited by 128
“Obese subjects have been reported to have significantly reduced circulating fasting and postprandial levels of PYY (139) and greater BMD (140).”
BackgroundThe Role of Fiber in Energy Balance
Hervik, A. K., & Svihus, B. (2019) · Journal of Nutrition and Metabolism · doi:10.1155/2019/4983657 · Cited by 124
Metabolic signals in human puberty: Effects of over and undernutrition
Martos‐Moreno, G. Á., Chowen, J. A., & Argente, J. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.12.017 · Cited by 144
The future role of gut hormones in the treatment of obesity
Troke, R. C., Tan, T. M., & Bloom, S. R. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 125
Self-citationAppetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Miller, G. D. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 124
A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans
Yi, M., Li, H., Wu, Z., Yan, J., Liu, Q., Ou, C., & Chen, M. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486225 · Cited by 137
Appetite Regulation: An Overview
Dhillo, W. S. (2007) · Thyroid · doi:10.1089/thy.2007.0018 · Cited by 126
“In addition, obese individuals do not have elevated levels of PYY3-36, and PYY3-36 reduces food intake in obese volunteers (130).”
Suzuki, S., Ramos, E. J. B., Gonçalves, C. G., Chen, C., & Meguid, M. M. (2005) · Surgery · doi:10.1016/j.surg.2005.05.013 · Cited by 126
“Effects of PYY [3-36] in rodent models of diabetes”
BackgroundThe role of gut hormone peptide YY in energy and glucose homeostasis: Twelve years on
Manning, S., & Batterham, R. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170404 · Cited by 124
Self-citationDietary Protein Intake and Bariatric Surgery Patients: A Review
Faria, S. L., Faria, O. P., Buffington, C. K., Cardeal, M. D. A., & Ito, M. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0441-y · Cited by 134
“PYY infusion has been shown to reduce energy intake in overweight subjects [46, 47].”
BackgroundDimitriadis, E., Daskalakis, M., Kampa, M., Peppe, A., Papadakis, J. A., & Melissas, J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31826e1846 · Cited by 125
Altered ghrelin and peptide YY responses to meals in bulimia nervosa
Kojima, S., Nakahara, T., Nagai, N., Muranaga, T., Tanaka, M., Yasuhara, D., Masuda, A., Date, Y., Ueno, H., Nakazato, M., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02176.x · Cited by 133
PYY3–36 Reinforces Insulin Action on Glucose Disposal in Mice Fed a High-Fat Diet
van den Hoek, A. M., Heijboer, A. C., Corssmit, E. P. M., Voshol, P. J., Romijn, J. A., Havekes, L. M., & Pijl, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.1949 · Cited by 122
New targets to treat obesity and the metabolic syndrome
Martin, K. A., Mani, M. V., & Mani, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.093 · Cited by 121
“Peripheral infusion of YY3–36 has dose-dependent anorectic effects in rodents (Batterham et al., 2003; Karra and Batterham, 2010) (Batterham et al.”
BackgroundLong‐term Exercise Training in Overweight Adolescents Improves Plasma Peptide YY and Resistin
Jones, T. E., Basilio, J. L., Brophy, P. M., McCammon, M. R., & Hickner, R. C. (2009) · Obesity · doi:10.1038/oby.2009.11 · Cited by 124
“Obese humans have lower premeal PYY concentrations, have lower postmeal PYY concentrations, and consume more calories compared to lean controls when both are presented with comparable food choices (15).”
BackgroundNeuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin
Berner, L. A., Brown, T. A., Lavender, J. M., Lopez, E., Wierenga, C. E., & Kaye, W. H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.018 · Cited by 140
Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study
Nematy, M., O'Flynn, J. E., Wandrag, L., Brynes, A. E., Brett, S. J., Patterson, M., Ghatei, M. A., Bloom, S. R., & Frost, G. S. (2005) · Critical Care · doi:10.1186/cc3957 · Cited by 131
“This is consistent with other studies of human subjects [7-10].”
BackgroundResultSelf-citationDietary Fiber in the Prevention and Treatment of Metabolic Syndrome: A Review
Aleixandre, A., & Miguel, M. (2008) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390701761886 · Cited by 138
“PYY (3-36) decreases appetite and food intake in lean and obese subjects, but whether dietary fiber intake alters PYY (3-36) levels is unknown (Batterham et al., 2003).”
BackgroundPeptide YY, appetite and food intake
le Roux, C. W., & Bloom, S. R. (2005) · Proceedings of The Nutrition Society · doi:10.1079/pns2005427 · Cited by 140
“In man infusion of PYY3–36 markedly decreases circulating ghrelin levels and attenuates the preprandial rise (Batterham et al. 2003).”
InfluentialSelf-citationIepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Peptide YY Is Secreted after Oral Glucose Administration in a Gender-Specific Manner
Kim, B.-J., Carlson, O. D., Jang, H.-J., Elahi, D., Berry, C., & Egan, J. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0409 · Cited by 118
PYY3‐36 as an anti‐obesity drug target
Boggiano, M. M., Chandler, P. C., Oswald, K. D., Rodgers, R. J., Blundell, J. E., Ishii, Y., Beattie, A. H., Holch, P., Allison, D. B., Schindler, M., et al. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00218.x · Cited by 120
“The first report on PYY plasma levels (total PYY; immunoassays to specifically quantify PYY3-36 are not yet available) suggested that PYY is low in obese individuals, that a PYY-deficiency may be contributing to their obesity, and, hence, that PYY replacement therapy might be useful (30).”
BackgroundInfluentialRevisiting the role of protein-induced satiation and satiety
Morell, P., & Fiszman, S. (2016) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2016.08.003 · Cited by 142
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Panickar, K. S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200431 · Cited by 126
Neural representations of hunger and satiety in Prader–Willi syndrome
Hinton, E. C., Holland, A. J., Gellatly, M., Soni, S., Patterson, M., Ghatei, M. A., & Owen, A. M. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803128 · Cited by 126
Self-citationGoldstone, A. P., Patterson, M., Kalingag, N., Ghatei, M. A., Brynes, A. E., Bloom, S. R., Grossman, A. B., & Korbonits, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032209 · Cited by 116
“Although the anorexigenic intestinal hormone PYY acutely reduces fasting and postprandial ghrelin levels in non-PWS subjects (20), the normal fasting and postprandial plasma levels of PYY in PWS in our study have excluded PYY deficiency as contributing to hyperghrelinemia in PWS.”
BackgroundMethodInfluentialSelf-citationGastrointestinal satiety signals in humans — Physiologic roles for GLP-1 and PYY ?
Beglinger, C., & Degen, L. P. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.048 · Cited by 117
Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery
Karra, E., Yousseif, A., & Batterham, R. L. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.01.006 · Cited by 126
Self-citationHormonal Regulators of Appetite
Austin, J., & Marks, D. (2009) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/141753 · Cited by 88
“Here, we will attempt to address how these insights might affect pediatric practice and highlight the importance in children.”
BackgroundAaboe, K., Knop, F. K., Vilsbøll, T., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01167.x · Cited by 112
“PYY3-36 is known to reduce food intake in both obese and lean patients, and PYY3-36 levels may be reduced in obesity [39].”
BackgroundField, B. C. T., Wren, A. M., Peters, V., Baynes, K. C. R., Martin, N. M., Patterson, M., Alsaraf, S., Amber, V., Wynne, K., Ghatei, M. A., et al. (2010) · Diabetes · doi:10.2337/db09-1859 · Cited by 112
“The test meal procedure was identical to that used in previous studies with PYY3–36 and oxyntomodulin (18,19,26).”
MethodSelf-citationAcetylcholine Regulates Ghrelin Secretion in Humans
Broglio, F., Gottero, C., Van Koetsveld, P., Prodam, F., Destefanis, S., Benso, A., Gauna, C., Hofland, L., Arvat, E., van der Lely, A. J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031517 · Cited by 114
“Recent studies suggested also that peptide YY and oxyntomodulin would exert an inhibitory action on ghrelin secretion because its circulating levels have been found reduced under chronic treatment with peptide YY (3–36) and oxyntomodulin in humans (39, 40).”
BackgroundDruce, M. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2005.073759 · Cited by 111
“Obese subjects have a lower fasting basal PYY and a diminished postprandial rise, but remain sensitive to the inhibitory effects on appetite following exogenous administration. Thus PYY 3–36 might constitute a candidate target for anti-obesity therapy.”
BackgroundPeptide YY Levels Are Elevated After Gastric Bypass Surgery
Chan, J. L., Mun, E. C., Stoyneva, V., Mantzoros, C. S., & Goldfine, A. B. (2006) · Obesity · doi:10.1038/oby.2006.25 · Cited by 115
“The demonstration that exogenous PYY3–36 administration in rodents and humans inhibits short-term food intake and/or reduces weight gain has generated substantial scientific interest in the potential use of this hormone as a therapeutic agent for obesity (4,6).”
BackgroundResultInfluentialGuo, Y., Ma, L., Enriori, P. J., Koska, J., Franks, P. W., Brookshire, T., Cowley, M. A., Salbe, A. D., DelParigi, A., & Tataranni, P. A. (2006) · Obesity · doi:10.1038/oby.2006.180 · Cited by 111
“Our study and others (12) have shown that circulating concentrations of PYY are low in obese individuals, suggesting a possible etiologic/pathophysiological role and a potential therapeutic opportunity.”
BackgroundInfluentialRomijn, J. A., Corssmit, E. P., Havekes, L. M., & Pijl, H. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302c9b0 · Cited by 114
Behary, P., Tharakan, G., Alexiadou, K., Johnson, N., Wewer Albrechtsen, N. J., Kenkre, J., Cuenco, J., Hope, D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 110
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citationGastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People
Roque, M. I. V., Camilleri, M., Stephens, D. A., Jensen, M. D., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.10.025 · Cited by 113
Weickert, M. O., Spranger, J., Holst, J. J., Otto, B., Koebnick, C., Möhlig, M., & Pfeiffer, A. F. H. (2006) · British Journal of Nutrition · doi:10.1017/bjn20061902 · Cited by 111
“Intravenous PYY[3-36] infusions for 90 min have been shown to decrease food intake for a 12 h post-infusion period, with plasma ghrelin levels only being altered for about 150 min (Batterham et al. 2003).”
BackgroundRecent developments in the pathophysiology of irritable bowel syndrome
El-Salhy, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7621 · Cited by 111
Diet in irritable bowel syndrome
El‐Salhy, M., & Gundersen, D. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0022-3 · Cited by 127
“Figure 2 Duodenal CCK cells in a healthy subject (A) and in a patient with [184,185].”
BackgroundA functional neuroimaging review of obesity, appetitive hormones and ingestive behavior
Burger, K. S., & Berner, L. A. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.04.025 · Cited by 110
“Circulating PYY is negatively correlated with BMI, however, following PYY infusion decreased meal intake observed in both obese and lean individuals [42].”
BackgroundAnti-obesity drugs and neural circuits of feeding
Adan, R. A. H., Vanderschuren, L. J. M. J., & ELAFLEUR, S. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.008 · Cited by 120
Plasma Ghrelin Concentrations Are Lower in Binge-Eating Disorder1–3
Geliebter, A., Gluck, M. E., & Hashim, S. A. (2005) · Journal of Nutrition · doi:10.1093/jn/135.5.1326 · Cited by 128
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Schiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 116
“Meal-induced PYY secretion is blunted in obese participants, but the anorexigenic effect of PYY seems intact (114).”
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D., Alsuhail, A., AlRajhi, S., Alotaibi, N., Alotaibi, K., AlAmri, S., Alghamdi, S., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 106
“This is due to people with this risk variant of the gene having higher circulating levels of ghrelin, causing them to feel hungrier [103].”
BackgroundPeptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa
Utz, A. L., Lawson, E. A., Misra, M., Mickley, D. W., Gleysteen, S., Herzog, D. B., Klibanski, A., & Miller, K. K. (2008) · Bone · doi:10.1016/j.bone.2008.03.007 · Cited by 114
“Studies in humans and rodents have shown that systemic PYY3–36 infusion decreases caloric intake, even in obese subjects [29,30].”
BackgroundBeck, E. J., Tapsell, L. C., Batterham, M. J., Tosh, S. M., & Huang, X.-F. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509992856 · Cited by 108
“It has been postulated that PYY has a role in the aetiology of human obesity due to negative correlation with BMI and the fact that injection of the active fraction of PYY, PYY3-36 decreases food intake in human subjects ((28)).”
BackgroundEvaluating the profound effect of gut microbiome on host appetite in pigs
Yang, H., Yang, M. J., Fang, S., Huang, X., He, M., Ke, S., Gao, J., Wu, J., Zhou, Y., Fu, H., et al. (2018) · BMC Microbiology · doi:10.1186/s12866-018-1364-8 · Cited by 123
“[33] also reported that protein inhibits food intake and appetite more than carbohydrate or fat in obese individuals.”
BackgroundBray, G. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0680124 · Cited by 108
Little, T. J., & Feinle‐Bisset, C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.038 · Cited by 117
“to be less in obese, when comparedwith lean, individuals [118].”
The modulatory role of high fat feeding on gastrointestinal signals in obesity
Duca, F. A., Sakar, Y., & Covașă, M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.05.005 · Cited by 127
Bottin, J. H., Swann, J. R., Cropp, E., Chambers, E. S., Ford, H. E., Ghatei, M. A., & Frost, G. S. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516001872 · Cited by 106
“PYY-like and GLP-1 immunoreactivity was measured with an established in-house RIA((24,25)).”
MethodInfluentialSelf-citationGut Microbiota: A Contributing Factor to Obesity
Harakeh, S. M., Khan, I., Kumosani, T., Barbour, E., Almasaudi, S. B., Bahijri, S. M., Alfadul, S. M., Ajabnoor, G. M. A., & Azhar, E. I. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00095 · Cited by 107
“(Chakraborti, 2015).”
BackgroundThe role of PYY in feeding regulation
Ueno, H., Yamaguchi, H., Mizuta, M., & Nakazato, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.09.011 · Cited by 105
Effects of Diet Soda on Gut Hormones in Youths With Diabetes
Brown, R. J., Walter, M., & Rother, K. I. (2012) · Diabetes Care · doi:10.2337/dc11-2424 · Cited by 105
“PYY acts as an anorectic hormone in both lean (15) and obese humans (16), although its secretion is attenuated in obesity (17).”
BackgroundTargeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“Similar to GLP1, PYY 3–36 exerts a potent ano-rexigenic effect in lean people and people with obesity, as demonstrated by infusion studies 58 .”
Gatta‐Cherifi, B., Matias, I., Vallée, M., Tabarin, A., Marsicano, G., Piazza, P. V., & Cota, D. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.165 · Cited by 116
Sloth, B., Davidsen, L., Holst, J. J., Flint, A., & Astrup, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2007 · Cited by 104
“(4) resulted in side effects after PYY3-36 infusion, primarily in the form of nausea and vomiting, whereas studies with lower plasma concentrations have not reported these side effects (2, 3, 12, 15).”
BackgroundEffect of Weight Loss by Diet or Gastric Bypass Surgery on Peptide YY3–36 Levels
Oliván, B., Teixeira, J., Bose, M., Bawa, B., Chang, T., Summe, H., Lee, H., & Laferrère, B. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a6cdb0 · Cited by 105
Peptide hormones and lipopeptides: from self‐assembly to therapeutic applications
Hutchinson, J. A., Burholt, S., & Hamley, I. W. (2017) · Journal of Peptide Science · doi:10.1002/psc.2954 · Cited by 115
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
Weston–Green, K., Huang, X., & Deng, C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.039 · Cited by 124
Nguyen, A. D., Mitchell, N. F., Lin, S., Macia, L., Yulyaningsih, E., Baldock, P. A., Enriquez, R. F., Zhang, L., Shi, Y.-C., Zolotukhin, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040191 · Cited by 104
“An additional potential contributor to the hypophagic phenotype of our Y1Y5 receptor deficient mice is concomitant obesity, which would be expected to induce hormonal changes known to reduce food intake, such as elevated circulating concentrations of leptin and the gut satiety hormone peptide YY [39–42].”
BackgroundPrinz, P., & Stengel, A. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16194 · Cited by 118
“Although PYY levels are reduced in obese patients, its anorexic effect is still visible after exogenous administration.(174) Therefore, PYY analogs and Y2 agonists were suggested as possible targets in the treatment of obesity.”
BackgroundMartin, C. K., Anton, S. D., Walden, H. M., Arnett, C., Greenway, F. L., & Williamson, D. A. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2007.03.016 · Cited by 114
Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms
Ji, Y., Lee, H., Kaura, S., Yip, J., Sun, H., Guan, L., Han, W., & Ding, Y. (2021) · Biomolecules · doi:10.3390/biom11111582 · Cited by 124
“The main role of PYY involves the central regulation of appetite [91].”
BackgroundBose, M., Machineni, S., Oliván, B., Teixeira, J., McGinty, J. J., Bawa, B., Koshy, N., Colarusso, A., & Laferrère, B. (2010) · Obesity · doi:10.1038/oby.2009.473 · Cited by 102
“The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway.”
BackgroundInfluentialGOSSELLIN, J., WREN, J. A., & SUNDERLAND, S. J. (2007) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2007.00863.x · Cited by 100
Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men
Degen, L., Drewe, J., Piccoli, F., Gräni, K., Oesch, S., Bunea, R., D'Amato, M., & Beglinger, C. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00734.2006 · Cited by 100
Scott, W. R., & Batterham, R. L. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00038.2011 · Cited by 100
“Dysregulation of PYY is implicated in obesity (12), and PYY secretion in response to feeding may be blunted in obese individuals (12).”
BackgroundSelf-citationNakahara, T., Kojima, S., Tanaka, M., Yasuhara, D., Harada, T., Sagiyama, K., Muranaga, T., Nagai, N., Nakazato, M., Nozoe, S.-I., et al. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.021 · Cited by 110
Miller, J. E., Rosenbloom, A. L., & Silverstein, J. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0284 · Cited by 161
Cheng, C. Y. Y., Chu, J. Y. S., & Chow, B. K. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.178 · Cited by 98
“…(Cck; Beglinger et al, 2001; Gibbs et al, 1973; Hewson et al, 1988; Kissileff et al, 1981), pancreatic polypeptide (PP) (Asakawa et al, 2003; Batterham et al, 2003a, b; Malaisse-Lagae et al, 1977; Ueno et al, 1999), peptide YY (Batterham et al, 2003a, b; Batterham et al, 2002; Challis et…”
BackgroundPediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 128
Gut hormones and appetite control
Hameed, S., Dhillo, W., & Bloom, Sr. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01492.x · Cited by 98
“The peripheral administration of PP to mice and humans reduces food intake (Malaisse-Lagae et al, 1977; Batterham et al, 2003b).”
InfluentialSelf-citationHormonal mechanisms of weight loss and diabetes resolution after bariatric surgery
Cummings, D. E., Overduin, J., Shannon, M. H., & Foster‐Schubert, K. E. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.03.208 · Cited by 107
“This nding is in marked contrast to the blunted prandial PYY esponse normally observed in nonoperated obese individals [82,97,110].”
BackgroundResultNeuropeptide Y Receptor Selective Ligands in the Treatment of Obesity
Kamiji, M. M., & Inui, A. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0003 · Cited by 108
PYY plays a key role in the resolution of diabetes following bariatric surgery in humans
Guida, C., Stephen, S. D., Watson, M., Dempster, N., Larraufie, P., Marjot, T., Cargill, T., Rickers, L., Pavlides, M., Tomlinson, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.040 · Cited by 97
“Serum total PYY levels were measured in obese patients before (mean ± SEM; BMI 47 ± 8.4) and six months after either gastric bypass or sleeve gastrectomy (SG; mean ± SEM; BMI 37.5 ± 7.4; p b 0.0001) and compared with healthy volunteers (mean ± SEM; BMI 22.24 ± 2.1) (Fig.”
InfluentialLipids, CHOs, proteins: Can all macronutrients put a ‘brake’ on eating?
Shin, H.-S., Ingram, J. R., McGill, A., & Poppitt, S. D. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.07.008 · Cited by 110
Koegler, F. H., Enriori, P. J., Billes, S. K., Takahashi, D. L., Martin, M. S., Clark, R. L., Evans, A. E., Grove, K. L., Cameron, J. L., & Cowley, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3198 · Cited by 98
Lin, S., Shi, Y.-C., Yulyaningsih, E., Aljanova, A., Zhang, L., Macia, L., Nguyen, A. D., Lin, E.-J. D., During, M. J., Herzog, H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008488 · Cited by 96
“Y2 receptors have also been flagged as potential targets for novel anti-obesity agents, since PYY3-36, an endogenous Y2-preferring ligand, reduces food intake in lean [8] and obese [9] humans and reduces body weight and adiposity after chronic administration to obese rodents [10,11].”
BackgroundInfluence of Running and Walking on Hormonal Regulators of Appetite in Women
Larson-Meyer, D. E., Palm, S., Bansal, A., Austin, K. J., Hart, A. M., & Alexander, B. M. (2012) · Journal of Obesity · doi:10.1155/2012/730409 · Cited by 95
“Peripheral infusion of both peptides at physiological concentrations markedly decrease food intake in humans [49, 50] which appears to be additive when infused simultaneously [51].”
BackgroundSteinert, R. E., & Beglinger, C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.039 · Cited by 116
Stucki, A. N., Daansen, P., Fuessl, M., Cieza, A., Huber, E. O., Atkinson, R. L., Kostanjsek, N. F. I., Stucki, G., & Ruof, J. (2004) · Journal of Rehabilitation Medicine · doi:10.1080/16501960410016064 · Cited by 99
“As supported by the literature ( 32 ), several experts indicated that gut hormones are an important area in obesity research.”
BackgroundPYY transgenic mice are protected against diet-induced and genetic obesity
Boey, D., Lin, S., Enriquez, R. F., Lee, N. J., Slack, K., Couzens, M., Baldock, P. A. J., Herzog, H., & Sainsbury, A. (2008) · Neuropeptides · doi:10.1016/j.npep.2007.11.003 · Cited by 99
“Obese subjects have significantly reduced circulating levels of PYY (Batterham et al., 2003).”
Glucocorticoids, stress and eating: The mediating role of appetite‐regulating hormones
Kuckuck, S., van der Valk, E. S., Scheurink, A. J. W., van der Voorn, B., Iyer, A. M., Visser, J. A., Delhanty, P. J. D., van den Berg, S. A. A., & van Rossum, E. F. C. (2022) · Obesity Reviews · doi:10.1111/obr.13539 · Cited by 105
“development and maintenance of obesity by reducing satiety signaling and thereby promoting overeating.(131,132,134,136) Indeed, a blunted postprandial PYY increase has been associated with more disinhibited/uncontrolled eating in healthy humans.”
BackgroundInteraction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men
Gutzwiller, J.-P., Degen, L., Matzinger, D., Prestin, S., & Beglinger, C. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00599.2003 · Cited by 94
“Further research is required to determine whether PYY(3-36) interacts with other satiety factors of the gastrointestinal tract.”
BackgroundInfluentialDiet: Friend or Foe of Enteroendocrine Cells: How It Interacts with Enteroendocrine Cells
Morán‐Ramos, S., Tovar, A. R., & Torres, N. (2012) · Advances in Nutrition · doi:10.3945/an.111.000976 · Cited by 111
“On the other hand, PYY3–36 has been shown to potently decrease appetite and reduce weight gain at physiological levels (80,82).”
BackgroundValderas, J. P., Irribarra, V., Boza, C., de la Cruz, R., Liberona, Y., Acosta, A. M., Yolito, M., & Maiz, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0983 · Cited by 92
Feltrin, K. L., Patterson, M., Ghatei, M. A., Bloom, S. R., Meyer, J. H., Horowitz, M., & Feinle‐Bisset, C. (2006) · Peptides · doi:10.1016/j.peptides.2006.01.023 · Cited by 108
Self-citation
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.